Home / Health / Rare Lung Cancer Strikes Younger Adults
Rare Lung Cancer Strikes Younger Adults
1 Feb
Summary
- ALK+ lung cancer is caused by a gene fusion, not inherited.
- Targeted tyrosine kinase inhibitors are effective treatments.
- Median age for ALK+ diagnosis is 50-52, often non-smokers.
ALK+ lung cancer, a rare subtype, arises from a random fusion of the ALK gene, not from inheritance. This genetic alteration causes cancer cells to divide uncontrollably. The discovery of this mutation less than 20 years ago paved the way for targeted treatments.
Tyrosine kinase inhibitors are the primary treatment, effectively halting cancer cell proliferation by blocking specific growth signals. Significant advancements have led to third-generation drugs now approved for NHS use. Approximately 5% of lung cancer diagnoses are ALK+.
This form of lung cancer presents differently from typical cases. The median age for diagnosis is 50-52, contrasting with the general lung cancer average of 74. It is more prevalent in never-smokers, and this low suspicion can result in late-stage diagnoses.
Recognizing the challenges patients face, a dedicated educational website has been launched to provide comprehensive information on ALK+ lung cancer for both patients and clinicians. This resource covers signs, symptoms, disease development, and treatment options.
